Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Tissue Repair Ltd ( (AU:TRP) ) has issued an update.
Tissue Repair Limited has appointed co-founder Peter Scutt as an Executive Director, effective 20 April 2026, and engaged him under a consultancy agreement to support the CEO on strategy for domestic and international market entry and distribution of TR Pro+ and other aesthetic and medical products. Scutt brings extensive experience from prior roles at Tissue Repair, Mable Technologies, Novogen, a U.S. venture capital fund, and Bankers Trust, and will work three days per week under a contract running to February 2027, signaling a strengthening of the company’s strategic and commercial leadership as it pursues broader market penetration.
More about Tissue Repair Ltd
Tissue Repair Limited (ASX: TRP) operates in the medical and aesthetic therapeutics sector, developing products based on a novel proprietary active ingredient for wound healing. The company’s portfolio includes TR Pro+ and additional aesthetic and medical products, with a focus on both onshore and offshore market entry, development and distribution strategies.
Average Trading Volume: 95,310
Technical Sentiment Signal: Sell
Current Market Cap: A$9.98M
For a thorough assessment of TRP stock, go to TipRanks’ Stock Analysis page.